We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Bispectral Index Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography (EndoBISs)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00952458
Recruitment Status : Completed
First Posted : August 6, 2009
Last Update Posted : August 24, 2012
Sponsor:
Collaborator:
Medtronic - MITG
Information provided by:
Technische Universität München

Brief Summary:
This randomized study investigates the benefits of an additional Bispectral Index monitoring of depth of sedation during endoscopic retrograde cholangiopancreaticography. A bispectral index (BIS) monitor is a neurophysiological monitoring device which continually analyses a patient's electroencephalograms during general anaesthesia to assess the level of consciousness during anaesthesia.

Condition or disease Intervention/treatment
Gastrointestinal Endoscopy Sedation Device: BIS monitoring

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 144 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Bispectral Index Monitoring as an Adjunct to Standard Monitoring of Sedation During Endoscopic Retrograde Cholangiopancreaticography
Study Start Date : July 2009
Primary Completion Date : May 2010
Study Completion Date : May 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Endoscopy
U.S. FDA Resources

Arm Intervention/treatment
Experimental: BIS monitoring
Dosing of sedatives with BIS monitoring
Device: BIS monitoring
Neuromonitoring of depth of sedation with Bispectral Index
No Intervention: Standard monitoring
Dosing of sedatives without BIS monitoring



Primary Outcome Measures :
  1. Cardiopulmonary complications of sedation [ Time Frame: 1-4 hours ]

Secondary Outcome Measures :
  1. Efficacy of sedation [ Time Frame: 1-4 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Indication for ERCP (Endoscopic Retrograde Cholangiopancreatography) with midazolam and propofol sedation

Exclusion Criteria:

  • Missing informed consent
  • ASA V
  • Preexisting neurological deficit
  • Known pregnancy
  • Hypotension (RRsys<90mmHg), bradycardia (HR<50/min), hypoxia (SaO2<90%)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00952458


Locations
Germany
Klinikum rechts der Isar der Technischen Universität München
Munich, Bavaria, Germany, 81675
Sponsors and Collaborators
Technische Universität München
Medtronic - MITG
Investigators
Principal Investigator: Stefan von Delius, MD Klinikum rechts der Isar der Technischen Universität München

Publications:
Responsible Party: II. Medizinische Klinik, Dr. Stefan von Delius, Klinikum rechts der Isar der Technischen Universität München
ClinicalTrials.gov Identifier: NCT00952458     History of Changes
Other Study ID Numbers: 2094/08
First Posted: August 6, 2009    Key Record Dates
Last Update Posted: August 24, 2012
Last Verified: May 2010

Keywords provided by Technische Universität München:
Safety
Midazolam and propofol sedation
ERCP
Bispectral Index monitoring